It is a challenge to identify the molecular networks contributing to the neural basis of human speech. Mutations in transcription factor FOXP2 cause difficulties mastering fluent speech (developmental verbal dyspraxia, DVD), while mutations of sushi-repeat protein SRPX2 lead to epilepsy of the rolandic (sylvian) speech areas, with DVD or with bilateral perisylvian polymicrogyria. Pathophysiological mechanisms driven by SRPX2 involve modified interaction with the plasminogen activator receptor (uPAR).
Introduction
The development and functioning of the brain depend on very precise and complicated molecular networks that must be regulated both in time and space. Animal models and human genetic analyses have identified a large number of proteins participating in crucial brain processes, but little is known about how these individual proteins organize in regulatory and interacting networks. Deciphering the neurogenetic pathways that are associated with speech-related circuits of the brain, while being of prime scientific importance, represents an even more challenging problem given that speech is a uniquely human trait. Nevertheless, in recent years progress has been made by studying families where impairment of speech-associated processes is inherited in a monogenic fashion. It has thus been possible to pinpoint genes that constitute key entry points into the molecular networks underlying such processes (1, 2) . In particular, rare loss-of-function mutations in the FOXP2 gene (OMIM 605317) can cause a severe speech and language disorder (OMIM 602081) (3) (4) (5) . FOXP2-related disorder is characterized by difficulties in mastering sequences of oral and facial movements, impairing speech articulation (developmental verbal dyspraxia, DVD), accompanied by additional problems with expressive and receptive language. FOXP2 belongs to a family of transcription factors that have crucial functions in a wide range of physiological processes and that are characterized by a forkhead-box (FOX) DNAbinding domain (6) . In addition to the generation and characterisation of various animal models (7-12), subsequent studies have focused on the identification of FOXP2-targeted promoter regions (13, 14) . At least some putative FOXP2-regulated genes are likely to represent important players in speech-associated pathways. Indeed, a recent study found that FOXP2 directly regulates the CNTNAP2 gene (OMIM 604569) which encodes a by guest on November 7, 2016 http://hmg.oxfordjournals.org/ Downloaded from 4 contactin-associated protein of the neurexin superfamily, and showed that polymorphisms in this target gene are associated with specific language impairment (15) .
Human genetic analyses have also implicated mutations of the sushi repeat protein SRPX2 (OMIM 300642) in a range of speech-related disorders. These include epileptic (rolandic/sylvian epilepsy), functional (DVD) and developmental (bilateral perisylvian polymicrogyria) disorders of the speech areas of the cortex (OMIM 300643, 300388) (16) . Several proteins that physically interact with SRPX2 have then been identified, suggesting involvement of the extracellular matrix proteolysis machinery in the pathology and physiology of speech-associated circuits. Most notably, SRPX2 was found to directly interact with uPAR (OMIM 173391), the plasminogen activator receptor of the urokinase type (also known as PLAUR), and the SRPX2/uPAR ligandreceptor interaction showed quantitative modification caused by pathogenic mutation of SRPX2 (17) .
Interestingly, the uPAR promoter region was identified among the top hundred potential FOXP2 targets in a high-throughput chromatin-immunoprecipitation microarray screen (ChIP-chip) using human neuronal models (14) . Given that FOXP2 and SRPX2 mutations cause related disorders of speech processing and associated brain areas, this observation raised the exciting possibility of a functional link between the FOXP2 transcription factor on the one hand, and the SRPX2/uPAR complex on the other hand. In the present study, we show that human FOXP2 down-regulates both the SRPX2 and the uPAR genes and that this transcriptional regulation is lost when FOXP2 bears a pathogenic p.R553H mutation that is known to cause DVD. Moreover, we report discovery of a new FOXP2 coding mutation in a patient with polymicrogyria of by guest on November 7, 2016 http://hmg.oxfordjournals.org/ Downloaded from 5 the left rolandic operculum and demonstrate that it partially impairs proper FOXP2 regulation of SRPX2 promoter activity. Our study thus identifies a novel genetic and regulatory network that is altered in disorders affecting speech processing and functioning/development of speech-related brain areas.
Results

Bioinformatic detection of FOX, FOXP and FOXP2 consensus binding sites in SRPX2
and uPAR promoters AATTTG and ATTTGT). The FOXP2 consensus sequence ATTTGT is contained within the FOXP sites and the FOXP sites also conform to the more general FOX sites (18) . The promoter regions of the human SRPX2 and of the human uPAR genes were screened in silico for the presence of FOX, FOXP and FOXP2 sites, including approximately 1.5 kb of DNA sequence 5' to each corresponding and canonical transcription start site (TSS) (SRPX2: Genbank NM_014467; uPAR: Genbank NM_002659). In silico and 5'-RACE (Rapid amplification of cDNA ends) PCR experiments confirmed that the SRPX2 and uPAR brain transcripts detected so far did not display any alternative and more distal 5' TSS (data not shown). Several consensus sequences of various types (FOX, FOXP, FOXP2) were identified in the promoter regions of both genes (Table 1, Figure S1 ). Seven sites (SRP1 to SRP7, from 3' to 5' of 6 the (+) strand) were identified for SRPX2: SRP1, SRP2, SRP5 and SRP7 were of the FOX type, and SRP3, SRP4 and SRP6 fitted the consensus for FOXP2. Six sites (UP1 to UP6) were detected for uPAR: UP1 to UP3 were of the FOX type, and UP4 to UP6
were of the FOXP type. Some of these sites (SRP1, UP2, UP5 and UP6) were composed of more than one consensus sequence. The presence of such consensus binding sites in silico was thus consistent with a possible regulation of SRPX2 and of uPAR by transcription factors of the FOX family. Notably, comparative searches of those consensus binding sites (SRP1-7 and UP1-6, respectively) in the Srpx2 and Upar promoter sequences from chimpanzee and mouse revealed subtle to dramatic differences with their human promoter counterparts, with the most obvious evolutionary modification being the lack of any of the UP1 to UP6 consensus forkhead binding site in the mouse Upar promoter region ( Figure S1 ).
FOXP2 expression leads to significant decrease in native SRPX2 and uPAR transcripts
The possible regulation of SRPX2 and uPAR by FOXP2 was then addressed by measuring by quantitative RT-PCR (qRT-PCR) the expression of these genes in the presence of exogenous human FOXP2 protein encoded by the major transcript of FOXP2 (isoform 1; Genbank NM_014491). When HEK293T cells were transfected with a construct expressing recombinant FOXP2 protein, SRPX2 mRNA levels were significantly reduced (43.6% decrease, P < 0.05, two-tailed unpaired t test) across replicate experiments as compared with control cells transfected with the corresponding non recombinant vector (Figure 1) . Similarly, the amounts of uPAR transcripts also showed significant and replicated decrease (38.6% decrease, P < 0.01, two-tailed 7 unpaired t test) in FOXP2-transfected cells (Figure 1 ). This indicated the existence of a functional link between FOXP2 and both the SRPX2 and the uPAR genes.
FOXP2 represses SRPX2 and uPAR promoters
We next tested whether expression of FOXP2 could modify the activities of the SRPX2 and of the uPAR promoters by using a luciferase reporter assay. The promoter regions of each gene as defined above were subcloned into the appropriate vector 
FOXP2 directly binds to consensus sites in the SRPX2 and uPAR promoters
Repression of the SRPX2 and uPAR promoter activities and transcript expressions by FOXP2, and the presence of FOX, FOXP and FOXP2 consensus binding sites within the promoter regions of SRPX2 and of uPAR, strongly suggested that FOXP2 could directly bind to these promoter regions. We tested this by carrying out electrophoretic mobility shift assays (EMSAs) for the 13 consensus binding sites (SRP1-7 and UP1-6) that had been detected in silico in the SRPX2 and uPAR promoter sequences ( Figure S1 , Table S1 ). Nuclear extracts were prepared from HEK293T cells transfected with FOXP2 expression construct (pcDNA4/HisMax-FOXP2). These extracts were able to bind to a positive control consensus FOXP2 site as previously shown (18) and to DNA probes corresponding to the UP2 and UP6 sites of the uPAR promoter region, as well as to the SRP1 and SRP2 sites of the SRPX2 promoter region ( Figure 3 , Figure S2 ). In contrast, no binding was observed when using nuclear extracts prepared from HEK293T cells transfected with empty construct (pcDNA4/HisMax; line pcDNA4 in each panel of Figure 3 ). The gel shifts that were observed with SRP1, SRP2, UP2 and UP6 probes were due to binding by FOXP2 protein, since addition of an N-terminal FOXP2 antibody caused larger complexes or "supershifts" to occur (line FOXP2Ab in each panel of Figure 3 ). By comparison, no supershift was obtained when a nonspecific IgG antibody was used. Binding to either of the SRP1, SRP2, UP2 and UP6 probes was specific, as demonstrated by competitive impairment with each corresponding unlabeled probe (lines UPwt2, UPwt6, SRwt1, SRwt2 of Figure 3 ). Moreover, mutant (Table S1 ) and unlabeled forms of SRP1, SRP2, UP2 and UP6 probes (lines UPmut2, UPmut6, SRmut1, SRmut2 of Figure 3 ) failed to compete with the FOXP2-binding abilities of their labeled and wild-type counterparts, as also shown 9 for an irrelevant NFK unlabeled probe. Altogether, these data demonstrated efficient specific binding of FOXP2 to consensus sites situated within the promoter regions of both the SRPX2 and uPAR genes.
Pathogenic mutation of FOXP2 disrupts its functional links with SRPX2 and uPAR
Rare mutations in transcription factor FOXP2 lead to DVD (3) (4) (5) ; hence, targets downstream to FOXP2 are obvious candidates for being involved in pathophysiological mechanisms. Based on the data presented above, SRPX2 and uPAR may be considered particularly strong candidates because of the demonstrated relationship between the SRPX2/uPAR complex and disorders of the speech cortex, including DVD itself (13, 14) . This question was addressed by studying the most well-characterised aetiological mutation of FOXP2 (p.R553H), assessing its functional effects on the SRPX2 and uPAR genes. p.R553H is a pathogenic substitution in the DNA-binding domain of the FOXP2 protein, found in all fifteen affected members of an extensively studied multigenerational family segregating speech and language disorder (the KE family) (3).
qRT-PCR experiments showed that, in contrast to wild-type FOXP2, p.R553H mutant FOXP2 showed a significant and complete loss of repression of native SRPX2
and uPAR expression (P < 0.001 and P < 0.01, respectively; two-tailed unpaired t test) ( Figure 4A ). Luciferase assays yielded consistent data; the p.R553H mutation led to significant losses of repression of SRPX2 and uPAR promoters as compared with wildtype FOXP2 (P < 0.0001 for each, two-tailed unpaired t test) ( Figure 4B ). There even was increased activity (P < 0.0001, two-tailed unpaired t test) of the SRPX2 promoter in the presence of mutant p.R553H FOXP2 ( Figure 4B Loss of down-regulation of SRPX2 and of uPAR by mutant FOXP2 could be partly due to disrupted nuclear localization (18) . Indeed, alteration of FOXP2 nuclear targeting was confirmed in the present study by immunocytochemistry with Xpress epitope antibody after transfection of HEK293T cells with tagged constructs allowing expression of wild-type or p.R553H FOXP2 ( Figure 5 ). While increased cytoplasmic localization was clearly detected as compared with wild type FOXP2, a proportion of mutant p.R553H FOXP2 protein still showed nuclear localization, consistent with previously published data (18) . FOXP2 DNA binding capabilities can be affected by the p.R553H substitution (18) and this question was thus more specifically addressed with respect to the SRPX2 (SRP1 and SRP2) and uPAR (UP2 and UP6) binding sites using the same EMSA procedure as described above. Mutant p.R553H FOXP2 not only displayed reduced binding to a previously defined consensus site used as a control (18), but also showed unambiguous impairment (of variable degree) in its ability to bind to the consensus SRP1, SRP2, UP2 and UP6 target sites in the promoter regions of SRPX2 and of uPAR ( Figure 3) .
A novel FOXP2 missense mutation in a patient with left opercular polymicrogyria partially impairs regulation of SRPX2
The regulatory link between FOXP2 and SRPX2 prompted us to screen for Figure 5C ). Luciferase reporter assays were then conducted and showed that the p.M406T mutation led to significant loss of repression of the SRPX2 promoter, as compared with wild-type FOXP2 (P < 0.0001, two-tailed unpaired t test) ( Figure 5D ). In contrast with p.R553H ( Figure 4B ), by guest on November 7, 2016 http://hmg.oxfordjournals.org/ Downloaded from p.M406T FOXP2 partially retained the ability to repress SRPX2 promoter activity, and had no effect on the repression of uPAR promoter activity ( Figure 5D ).
Discussion
The present study characterized a novel molecular regulatory network associated with disorders of cortical speech areas and of speech processing. In particular, we demonstrated direct down-regulation of SRPX2, a gene implicated in X-linked rolandic epilepsy (RE) associated with DVD (RESDX syndrome) or with bilateral perisylvian polymicrogyria (16) , by the FOXP2 transcription factor, mutated in people with autosomal dominant DVD (3) (4) (5) . Similarly, FOXP2 also down-regulated the uPAR gene, which encodes a receptor of SRPX2 receptor, that in turn displays modified 13 of FOXP2 to less stringent FOX or FOXP sites has already been observed (14) .
Amongst the four FOXP2 binding sites studied here, three (SRP1, UP2 and UP6) consisted of more than one forkhead consensus sequence; this situation would be consistent with the binding of FOXP2 through homo-or heterodimerization, as already proposed (20) , and may also favor cross-binding to FOX and FOXP consensus sites.
Both the regulations of SRPX2 and of uPAR were abolished by a p.R553H FOXP2 mutation that is known to cause DVD (3); expression of p.R553H FOXP2 even led to significant increases in the activity of the SRPX2 promoter as compared with the control situation. This latter result is in line with previous investigations of the p.R553H mutant form using the SV40 promoter as a reporter (18) The data presented here demonstrated the existence of a novel regulatory and functional link, FOXP2-SRPX2/uPAR, displaying impairment in various disorders involving speech-related areas and networks. These findings are reminiscent of the recent functional link that was found between FOXP2 and the gene coding for the contactin associated protein-like 2, CNTNAP2 (15) . While FOXP2 mutations cause DVD accompanied by expressive and receptive language deficits, CNTNAP2 shows genetic association with specific language impairment (15) but also with autism (21) (22) (23) and with epilepsy and schizophrenia (24) . Moreover, a homozygous CNTNAP2 mutation in Amish children has been shown to cause focal epilepsy followed by shows enriched expression in frontal grey matter of human foetal brain tissue (33) , and FOXP2 itself displays high levels of expression in the developing perisylvian cortex (34) . Secondly, p.M406T was neither found in 222 control individuals nor in available databases of human variation. Furthermore, the methionine residue that is mutated is highly conserved across evolution, and p.M406T occurred in a leucine zipper domain that is crucial for dimerization and subsequent DNA binding of FOXP2 (20) . Thirdly, the present study showed that there is direct functional link between FOXP2 and the SRPX2/uPAR complex that in turn has been implicated in bilateral perisylvian polymicrogyria that predominated on the left side (16, 17) . More importantly, p.M406T was shown here to have functional consequences in vitro: it not only led to altered pattern of nuclear localization of FOXP2, but also to significantly reduced -albeit still active -regulation of the SRPX2 promoter activity; interestingly also, the promoter activity of uPAR remained unchanged. Hence the effect of p.M406T was more subtle than that of p.R553H. This is consistent with the difference in the genetic influences associated with those two mutant FOXP2 proteins. p.M406T retained partial functionality and the effects of this risk factor are likely to be modulated by genomic background, environmental influences, and stochastic developmental events, hence leading to incomplete penetrance in the pedigree reported here. Although the existence of compound heterozygous mutation cannot be firmly excluded, no other FOXP2 mutation was found in the patient and her mother and conventional as well as molecular FOXP2 shows evidence of recent positive selection (35) . FOXP2 underwent two non-synonymous changes since the human-chimpanzee split and cell-based studies suggest that several FOXP2 target genes may be differentially regulated by human and chimpanzee versions of the protein (36) . SRPX2 also exhibited an accelerated rate of non-synonymous substitutions in the human lineage; although there was insufficient statistical power to demonstrate the action of positive selection (37), the human-specific SRPX2 evolutionary change was associated with modified interaction with uPAR (17) .
From this evolutionary viewpoint, differences in the regulation of expression of SRPX2
and of uPAR by FOXP2 in different species might have been important. The SRP2 consensus site is conserved in the mouse and chimpanzee Srpx2 promoters. In contrast, SRP1, while being slightly different between the human and chimpanzee promoters, was not detected in the mouse Srpx2 promoter. Interestingly, the UP2 and UP6 FOXP2 binding sites of the human uPAR promoter region were conserved between human and chimpanzee but did not exist at all in the promoter region of murine Upar. Although preliminary, these data may suggest that the regulations by FOXP2 of uPAR and of SRPX2, have appeared or have been modified during evolution since the rodent-primate split.
Generally, the functioning and development of brain circuits underlying human speech result from complex sequential processes that must be tightly regulated. The emerging picture arising from the study of various speech-related disorders (RE, DVD, by guest on November 7, 2016 http://hmg.oxfordjournals.org/ Downloaded from BPP) is that of a complicated and intertwined network of regulation and interaction comprising FOXP2, uPAR, SRPX2 as well as CNTNAP2. Moreover, the situation is likely to be considerably more complex: FOXP2 certainly has many more functional targets (13, 14) , and uPAR (38, 39) as well as SRPX2 (40, 41) expression can be modulated by other transcription factors. In addition to uPAR, SRPX2 itself has many more possible partners (17) , some of which such as FBN1 (Fibrillin-1) or PCSK6 (Subtilisin-like proprotein convertase 4, PACE4) also showed significant enrichment after ChIP-chip FOXP2 experiments (14) . It is thus expected that alterations of several other molecular pathways will be found in future studies of speech-related syndromes.
As such, it will be crucial to identify and study each of them, and then try to integrate how and when they may interfere with each other and with the development/functioning of speech-related areas and networks. From this viewpoint, the identification of the FOXP2-SRPX2/uPAR functional and genetic link, and its alteration by a FOXP2 pathogenic mutation, represent important entry points for deciphering the complicated regulatory networks of molecules that go awry in speech-related disorders. Together with recently described FOXP2-CNTNPA2 genetic and SRPX2/uPAR proteomic links, the present findings make novel genetic and molecular links between distinct phenotypes that share clinical, epidemiological and neurobiological features, including autism, epilepsy of speech-related areas, and developmental speech and language disorders.
Materials and Methods
In silico analyses and 5'-RACE (rapid amplification of cDNA ends) experiments
The promoter regions of the human SRPX2 (Genbank NM_014467) and uPAR (Promega) on a LB9507 Luminometer (Lumat). LacZ activity was measured using the β-Galactosidase Enzyme Assay System (Promega) on a NanoDrop TM 1000 (Thermo 22 Fisher Scientific). All transfections were performed in triplicate and repeated in three independent experiments (nine biological replicates in total). The relative luciferase activities were then calculated with correction for transfection by β-Galactosidase activity. Data were expressed as mean ± SEM. Statistical significance was assessed using unpaired t tests (two-tailed).
EMSA experiments
HEK293T nuclear extracts (transfected with FOXP2, FOXP2.R553H, or the pcDNA4 empty vector control) were prepared as described previously (18) . Probes were designed as 24-30 nucleotide oligomers (Table S1 ) based around the predicted binding sites in the SRPX2 and uPAR promoters (Table 1) . Mutant promoters were the same, however with the core predicted binding site replaced (Table S1 ). A consensus probe previously shown to be efficiently bound by FOXP2 was used as a positive control (5'-agcttaaacaagacaacacaaataa), and an irrelevant promoter sequence (corresponding to an NFK binding site) was used as a negative control (5'-agctccgggggtgatttcactccccg). Oligonucleotide labeling and DNA binding reactions were performed as described previously (18) . Where unlabeled competitor probes were used to confirm specificity of DNA binding, they were added in 10-fold excess and pre- and the data were analyzed with the Genalys 3.0 software (43) .
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